Pub Date : 2024-11-01DOI: 10.26355/eurrev_202411_36913
E Uzunhisarcıklı
Objective: This study aimed to investigate the effect of psoralidin, a natural phenolic coumarin compound, on MK-801-induced neurotoxicity that may cause Alzheimer's disease and to determine the phosphodiesterase (PDE)-related molecular mechanism of action.
Materials and methods: In this study, neurotoxicity was performed using the MK-801 in the HT-22 cell line. The effects of compounds on the proliferation of HT-22 cells were determined by Real-Time Cell Analysis (RTCA). After measuring the total protein concentration, the PDE4A protein level was determined using the Western blot method.
Results: Psoralidin (100, 200, 400 µM) has been shown to have a neuroprotective effect against MK-801-induced neurotoxicity, as indicated by Real-Time Cell Analysis. In HT-22 cells, the half maximal effective concentration (EC50) value of psoralidin was calculated to be 230.4 µM, IC50 value of MK-801 was calculated to be 62.4 µM at 24 hours. It has been determined that psoralidin (200, 400 µM) inhibits PDE4A by using the Western blot method.
Conclusions: This research uncovers that psoralidin has neuroprotective effects in MK801-associated accumulation of the excitatory amino acid glutamate neurodegeneration and Alzheimer's disease.
{"title":"Potential PDE4A inhibition-mediated neuroprotective effects of psoralidin.","authors":"E Uzunhisarcıklı","doi":"10.26355/eurrev_202411_36913","DOIUrl":"10.26355/eurrev_202411_36913","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the effect of psoralidin, a natural phenolic coumarin compound, on MK-801-induced neurotoxicity that may cause Alzheimer's disease and to determine the phosphodiesterase (PDE)-related molecular mechanism of action.</p><p><strong>Materials and methods: </strong>In this study, neurotoxicity was performed using the MK-801 in the HT-22 cell line. The effects of compounds on the proliferation of HT-22 cells were determined by Real-Time Cell Analysis (RTCA). After measuring the total protein concentration, the PDE4A protein level was determined using the Western blot method.</p><p><strong>Results: </strong>Psoralidin (100, 200, 400 µM) has been shown to have a neuroprotective effect against MK-801-induced neurotoxicity, as indicated by Real-Time Cell Analysis. In HT-22 cells, the half maximal effective concentration (EC50) value of psoralidin was calculated to be 230.4 µM, IC50 value of MK-801 was calculated to be 62.4 µM at 24 hours. It has been determined that psoralidin (200, 400 µM) inhibits PDE4A by using the Western blot method.</p><p><strong>Conclusions: </strong>This research uncovers that psoralidin has neuroprotective effects in MK801-associated accumulation of the excitatory amino acid glutamate neurodegeneration and Alzheimer's disease.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4546-4552"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.26355/eurrev_202411_36906
X Wang, F Yu, W-Q Zheng
The article "Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS" by X. Wang, F. Yu, W.-Q. Zheng, published in Eur Rev Med Pharmacol Sci 2019; 23 (3 Suppl): 294-303-DOI: 10.26355/eurrev_201908_18660-PMID: 31389594 has been retracted by the Editor in Chief. The authors contacted the journal in June 2024, requesting to withdraw the article. Following this request, the journal discovered that the article was commented on PubPeer (link: https://pubpeer.com/publications/DE4E22B2B9E506EDC2E650C58152E0). The journal started an investigation and asked the authors to provide answers to the concerns raised as well as to send the raw data. Following the journal's requests, the authors neither responded nor provided the raw data. The journal's investigation revealed duplications between panels Blank, HG+1 umol/l, and HG+10 umol/l of Figure 4A. Consequently, the Editor in Chief mistrusts the results presented and has decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18660.
文章 "Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS "由X. Wang, F. Yu, W.-Q. Zheng发表在Eur Rev Med Pharmacol Sci 2019; 23 (3 Supp.): Eur Rev Med Pharmacol Sci上。郑,发表于《Eur Rev Med Pharmacol Sci 2019; 23 (3 Suppl):294-303-DOI: 10.26355/eurrev_201908_18660-PMID: 31389594 已被主编撤回。作者于 2024 年 6 月联系本刊,要求撤稿。在提出这一请求后,期刊发现该文章在 PubPeer(链接:https://pubpeer.com/publications/DE4E22B2B9E506EDC2E650C58152E0)上发表了评论。期刊开始调查,并要求作者对提出的问题做出答复,并发送原始数据。在期刊提出要求后,作者既没有回复,也没有提供原始数据。期刊的调查发现,图 4A 的空白、HG+1 umol/l 和 HG+10 umol/l 三组数据存在重复。因此,主编对所提供的结果不信任,决定撤回这篇文章。本文已被撤稿。https://www.europeanreview.org/article/18660。
{"title":"Retraction Note: Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS.","authors":"X Wang, F Yu, W-Q Zheng","doi":"10.26355/eurrev_202411_36906","DOIUrl":"10.26355/eurrev_202411_36906","url":null,"abstract":"<p><p>The article \"Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS\" by X. Wang, F. Yu, W.-Q. Zheng, published in Eur Rev Med Pharmacol Sci 2019; 23 (3 Suppl): 294-303-DOI: 10.26355/eurrev_201908_18660-PMID: 31389594 has been retracted by the Editor in Chief. The authors contacted the journal in June 2024, requesting to withdraw the article. Following this request, the journal discovered that the article was commented on PubPeer (link: https://pubpeer.com/publications/DE4E22B2B9E506EDC2E650C58152E0). The journal started an investigation and asked the authors to provide answers to the concerns raised as well as to send the raw data. Following the journal's requests, the authors neither responded nor provided the raw data. The journal's investigation revealed duplications between panels Blank, HG+1 umol/l, and HG+10 umol/l of Figure 4A. Consequently, the Editor in Chief mistrusts the results presented and has decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18660.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4491"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.26355/eurrev_202411_36955
Y-M Zhang, J-K Fan, X-Y Wang, J Liu, T Li, X-S Wang, X-J Yang
Objective: This study aimed to investigate the expression levels of the MKNK2 gene in pan-cancer, its prognostic significance, and its relationship with the tumor immune microenvironment, as well as to assess its potential as an immunological and prognostic biomarker.
Materials and methods: The research utilized data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Cancer Cell Line Encyclopedia (CCLE), including clinical and mutational information. Bioinformatic tools were employed to analyze the association of MKNK2 with carcinogenesis, including its links to prognosis, immune cell infiltration, tumor immune microenvironment, gene mutation, and the stemness of various tumor cells. A variety of statistical software and analytical tools were applied, including R software, SPSS 27.0, TIMER, CIBERSORT algorithm, and EPIC algorithm.
Results: The study found that MKNK2 is abnormally expressed in pan-cancer and is associated with a poor prognosis. The levels of MKNK2 are highly related to immune cell infiltration and tumor stemness. Notably, in liver hepatocellular carcinoma, glioblastoma multiforme, low-grade gliomas, and acute myeloid leukemia, MKNK2 expression shows a strong correlation with clinical outcomes and immune infiltration. Furthermore, the expression of MKNK2 shows significant correlations with immune cell infiltration, immune checkpoints, tumor mutational burden (TMB), microsatellite instability (MSI), and stemness scores across various cancers.
Conclusions: The abnormal expression of MKNK2 is associated with tumor progression, immune checkpoint genes, immune cell infiltration, microsatellite instability (MSI), tumor mutational burden (TMB), and stemness in a variety of tumors, especially in glioblastoma multiforme low-grade gliomas (GBMLGG). Therefore, MKNK2 may serve as a potent prognostic physiological marker and provide new avenues for the development of tumor mechanisms and therapeutic strategies targeting MKNK2 to enhance the efficacy of immunotherapy.
{"title":"Study on MKNK2 as a potential prognostic and immunological biomarker in pan-cancer.","authors":"Y-M Zhang, J-K Fan, X-Y Wang, J Liu, T Li, X-S Wang, X-J Yang","doi":"10.26355/eurrev_202411_36955","DOIUrl":"https://doi.org/10.26355/eurrev_202411_36955","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the expression levels of the MKNK2 gene in pan-cancer, its prognostic significance, and its relationship with the tumor immune microenvironment, as well as to assess its potential as an immunological and prognostic biomarker.</p><p><strong>Materials and methods: </strong>The research utilized data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Cancer Cell Line Encyclopedia (CCLE), including clinical and mutational information. Bioinformatic tools were employed to analyze the association of MKNK2 with carcinogenesis, including its links to prognosis, immune cell infiltration, tumor immune microenvironment, gene mutation, and the stemness of various tumor cells. A variety of statistical software and analytical tools were applied, including R software, SPSS 27.0, TIMER, CIBERSORT algorithm, and EPIC algorithm.</p><p><strong>Results: </strong>The study found that MKNK2 is abnormally expressed in pan-cancer and is associated with a poor prognosis. The levels of MKNK2 are highly related to immune cell infiltration and tumor stemness. Notably, in liver hepatocellular carcinoma, glioblastoma multiforme, low-grade gliomas, and acute myeloid leukemia, MKNK2 expression shows a strong correlation with clinical outcomes and immune infiltration. Furthermore, the expression of MKNK2 shows significant correlations with immune cell infiltration, immune checkpoints, tumor mutational burden (TMB), microsatellite instability (MSI), and stemness scores across various cancers.</p><p><strong>Conclusions: </strong>The abnormal expression of MKNK2 is associated with tumor progression, immune checkpoint genes, immune cell infiltration, microsatellite instability (MSI), tumor mutational burden (TMB), and stemness in a variety of tumors, especially in glioblastoma multiforme low-grade gliomas (GBMLGG). Therefore, MKNK2 may serve as a potent prognostic physiological marker and provide new avenues for the development of tumor mechanisms and therapeutic strategies targeting MKNK2 to enhance the efficacy of immunotherapy.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 22","pages":"4591-4620"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.26355/eurrev_202411_36907
No Authors Listed
The Editor in Chief and the Publisher are issuing an expression of concern to alert readers that the following article is under investigation due to a potential ethical breach regarding lack of transparency in the transplantation procedure as outlined in the article published by Rogers W et al (DOI: 10.1136/bmjopen-2018-024473): - Chen J, Zhong L. Clinical significance of serum hepcidin-25 levels in predicting invasive fungal disease in patients after transplantation. Eur Rev Med Pharmacol Sci 2013; 17 (13): 1769-1773-PMID: 23852902. Further updates will be provided once the investigation is completed. The authors have been notified about the ongoing investigation and the publication of this expression of concern.
主编和出版人特此提醒读者,以下文章正在接受调查,原因是Rogers W等人发表的文章(DOI: 10.1136/bmjopen-2018-024473)中所述的移植过程缺乏透明度,可能违反了伦理道德:- Chen J, Zhong L. 血清血红素-25水平在预测移植后患者侵袭性真菌病中的临床意义。Eur Rev Med Pharmacol Sci 2013; 17 (13):1769-1773-PMID: 23852902.一旦调查完成,我们将提供进一步的更新信息。有关正在进行的调查和本关注声明的发布已通知作者。
{"title":"Expression of Concern.","authors":"No Authors Listed","doi":"10.26355/eurrev_202411_36907","DOIUrl":"10.26355/eurrev_202411_36907","url":null,"abstract":"<p><p>The Editor in Chief and the Publisher are issuing an expression of concern to alert readers that the following article is under investigation due to a potential ethical breach regarding lack of transparency in the transplantation procedure as outlined in the article published by Rogers W et al (DOI: 10.1136/bmjopen-2018-024473): - Chen J, Zhong L. Clinical significance of serum hepcidin-25 levels in predicting invasive fungal disease in patients after transplantation. Eur Rev Med Pharmacol Sci 2013; 17 (13): 1769-1773-PMID: 23852902. Further updates will be provided once the investigation is completed. The authors have been notified about the ongoing investigation and the publication of this expression of concern.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4492"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.26355/eurrev_202411_36910
Z Teke, A Bisgin, C Oruc Rencuzogullari, K Eren Erdogan, C K Parsak, S Kalkanli Tas
Objective: Next-generation sequencing (NGS) has been offered as a large-scale and effective genomic analyzing tool. In this research, we seek to examine the possible benefits of an actionable mutation panel in association with clinical and pathological features in the treatment of esophageal cancer.
Patients and methods: In our study, 85 cases whose diagnosis of carcinoma was confirmed histopathologically either by endoscopic biopsy or esophageal surgery between 2010 and 2020 were identified from the hospital database. In formalin-fixed, paraffin-embedded tumor samples, a total of 20 genes of AKT1, ALK, BRAF, DDR, EGFR, ERBB2, ERBB3, ESR1, FGFR1, KIT, KRAS, MAP2K1, MET, NRAS, NTRK, PDGFRA, PIK3CA, PTEN, RICTOR and ROS1 were analyzed via NGS for actionable mutations.
Results: Of 85 cases, 47 patients (55.3%) were men and 38 (44.7%) were women, and the mean age of the patients was 58.01±11.45 years. There were substantial distinctions in the variables of pathogenicity of variant, operation type, stage, and both lymphovascular and perineural invasion (p<0.05). Most of the primary tumors were situated in the lower thoracic esophagus (n=23; 27%). PIK3CA variant was the highest in number among the variant types (n=17) and was detected in 41.2% of the lower thoracic tumors. The increases in mutation numbers of >2 were especially concentrated in the lower thoracic esophageal carcinomas.
Conclusions: The utility of an actionable multigene panel revealed the value of a well-designed NGS workflow in the practical use of clinical outcomes via the prediction of responsiveness to therapeutic agents or indications for novel treatment modalities in addition to the estimation of prognosis.
{"title":"Prognostic significance of actionable next-generation sequencing multigene panel in esophageal cancer treatment.","authors":"Z Teke, A Bisgin, C Oruc Rencuzogullari, K Eren Erdogan, C K Parsak, S Kalkanli Tas","doi":"10.26355/eurrev_202411_36910","DOIUrl":"10.26355/eurrev_202411_36910","url":null,"abstract":"<p><strong>Objective: </strong>Next-generation sequencing (NGS) has been offered as a large-scale and effective genomic analyzing tool. In this research, we seek to examine the possible benefits of an actionable mutation panel in association with clinical and pathological features in the treatment of esophageal cancer.</p><p><strong>Patients and methods: </strong>In our study, 85 cases whose diagnosis of carcinoma was confirmed histopathologically either by endoscopic biopsy or esophageal surgery between 2010 and 2020 were identified from the hospital database. In formalin-fixed, paraffin-embedded tumor samples, a total of 20 genes of AKT1, ALK, BRAF, DDR, EGFR, ERBB2, ERBB3, ESR1, FGFR1, KIT, KRAS, MAP2K1, MET, NRAS, NTRK, PDGFRA, PIK3CA, PTEN, RICTOR and ROS1 were analyzed via NGS for actionable mutations.</p><p><strong>Results: </strong>Of 85 cases, 47 patients (55.3%) were men and 38 (44.7%) were women, and the mean age of the patients was 58.01±11.45 years. There were substantial distinctions in the variables of pathogenicity of variant, operation type, stage, and both lymphovascular and perineural invasion (p<0.05). Most of the primary tumors were situated in the lower thoracic esophagus (n=23; 27%). PIK3CA variant was the highest in number among the variant types (n=17) and was detected in 41.2% of the lower thoracic tumors. The increases in mutation numbers of >2 were especially concentrated in the lower thoracic esophageal carcinomas.</p><p><strong>Conclusions: </strong>The utility of an actionable multigene panel revealed the value of a well-designed NGS workflow in the practical use of clinical outcomes via the prediction of responsiveness to therapeutic agents or indications for novel treatment modalities in addition to the estimation of prognosis.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4515-4525"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.26355/eurrev_202411_36908
S Yavuz, U Y Malkan
Objective: Standard treatment for adults with acute myeloid leukemia (AML) involves anthracycline and cytarabine, while alternative regimens are necessary for elderly and frail patients. This study aims to compare the effectiveness and safety of various induction regimens in AML patients.
Patients and methods: The retrospective study included 130 adult AML patients treated at a tertiary care center from January 2014 to December 2022. Patients received one of the following induction regimens: anthracycline and cytarabine (n = 82), azacitidine and venetoclax (n = 11), etoposide and cytarabine (n = 22), or reduced-dose anthracycline and cytarabine (n = 15). Data on demographics, clinical characteristics, treatment-related toxicities, and infectious complications were collected. Outcomes included overall survival and remission rates.
Results: The anthracycline and cytarabine regimen demonstrated the highest overall survival rate, although remission rates did not significantly differ among the treatment groups. Patients receiving azacitidine and venetoclax experienced a significantly longer duration of neutropenia. The use of antiviral prophylaxis increased over the study period, reflecting improved management strategies. Infection remained the leading cause of mortality.
Conclusions: Effective management of prolonged neutropenia and infections is crucial for improving patient outcomes. Future research should focus on optimizing prophylactic and infection treatment strategies to further enhance survival in AML.
{"title":"Comparison of regimens targeting complete remission in the first-line treatment of acute myeloid leukemia patients.","authors":"S Yavuz, U Y Malkan","doi":"10.26355/eurrev_202411_36908","DOIUrl":"10.26355/eurrev_202411_36908","url":null,"abstract":"<p><strong>Objective: </strong>Standard treatment for adults with acute myeloid leukemia (AML) involves anthracycline and cytarabine, while alternative regimens are necessary for elderly and frail patients. This study aims to compare the effectiveness and safety of various induction regimens in AML patients.</p><p><strong>Patients and methods: </strong>The retrospective study included 130 adult AML patients treated at a tertiary care center from January 2014 to December 2022. Patients received one of the following induction regimens: anthracycline and cytarabine (n = 82), azacitidine and venetoclax (n = 11), etoposide and cytarabine (n = 22), or reduced-dose anthracycline and cytarabine (n = 15). Data on demographics, clinical characteristics, treatment-related toxicities, and infectious complications were collected. Outcomes included overall survival and remission rates.</p><p><strong>Results: </strong>The anthracycline and cytarabine regimen demonstrated the highest overall survival rate, although remission rates did not significantly differ among the treatment groups. Patients receiving azacitidine and venetoclax experienced a significantly longer duration of neutropenia. The use of antiviral prophylaxis increased over the study period, reflecting improved management strategies. Infection remained the leading cause of mortality.</p><p><strong>Conclusions: </strong>Effective management of prolonged neutropenia and infections is crucial for improving patient outcomes. Future research should focus on optimizing prophylactic and infection treatment strategies to further enhance survival in AML.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4493-4506"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.26355/eurrev_202411_36957
K Sridharan, A Jassim, A M Qader, M M Qader
Objective: End-stage renal disease (ESRD) commonly manifests with disrupted calcium balance, leading to renal osteodystrophy. We posited that variations in the genetic makeup of vitamin D and calcium-sensing receptors, specifically single nucleotide polymorphisms (SNPs), could affect calcium homeostasis. This study aimed to identify the genetic predictors related to vitamin D and calcium-sensing receptors on calcium metabolism using machine learning algorithm analysis in ESRD.
Patients and methods: We conducted a cross-sectional analysis on adults with ESRD. We gathered comprehensive demographic data and medical history. Blood samples were collected to measure SNPs, and a panel of calcium metabolism biomarkers associated with the calcium-sensing receptor and vitamin D receptor. The biomarkers included calcium, phosphate, vitamin D, parathyroid hormone (PTH), sclerostin, procollagen type 1 alpha 1, osteocalcin, and bone-specific alkaline phosphatase. We utilized machine learning algorithms to pinpoint genetic markers predictive of vitamin D deficiency.
Results: We found a notable decrease in serum procollagen type 1 alpha 1 levels among individuals with the CC of rs10190 (related to the calcium-sensing receptor) compared to those with the TT genotype and in those with the TT of rs739837 (pertaining to the vitamin D receptor) compared to the GG genotype. Similarly, the TT genotype of rs10190 was associated with significantly lower serum phosphate levels compared to CC and CT genotypes. Additionally, a lower serum PTH level was noted in individuals with the CT of rs1802757 (calcium-sensing receptor) compared to those with the CC genotype. Our machine learning analysis identified rs2221266 and rs1042636 as the most significant SNPs linked to vitamin D deficiency, demonstrating considerable predictive accuracy.
Conclusions: Our findings indicate that specific single nucleotide polymorphisms in the vitamin D and calcium-sensing receptors significantly influence calcium metabolism biomarkers in ESRD patients. Assessing the clinical implications of these genetic variations is crucial for advancing personalized medicine in renal care.
{"title":"Influence of vitamin D and calcium-sensing receptor gene variants on calcium metabolism in end-stage renal disease: insights from machine learning analysis.","authors":"K Sridharan, A Jassim, A M Qader, M M Qader","doi":"10.26355/eurrev_202411_36957","DOIUrl":"https://doi.org/10.26355/eurrev_202411_36957","url":null,"abstract":"<p><strong>Objective: </strong>End-stage renal disease (ESRD) commonly manifests with disrupted calcium balance, leading to renal osteodystrophy. We posited that variations in the genetic makeup of vitamin D and calcium-sensing receptors, specifically single nucleotide polymorphisms (SNPs), could affect calcium homeostasis. This study aimed to identify the genetic predictors related to vitamin D and calcium-sensing receptors on calcium metabolism using machine learning algorithm analysis in ESRD.</p><p><strong>Patients and methods: </strong>We conducted a cross-sectional analysis on adults with ESRD. We gathered comprehensive demographic data and medical history. Blood samples were collected to measure SNPs, and a panel of calcium metabolism biomarkers associated with the calcium-sensing receptor and vitamin D receptor. The biomarkers included calcium, phosphate, vitamin D, parathyroid hormone (PTH), sclerostin, procollagen type 1 alpha 1, osteocalcin, and bone-specific alkaline phosphatase. We utilized machine learning algorithms to pinpoint genetic markers predictive of vitamin D deficiency.</p><p><strong>Results: </strong>We found a notable decrease in serum procollagen type 1 alpha 1 levels among individuals with the CC of rs10190 (related to the calcium-sensing receptor) compared to those with the TT genotype and in those with the TT of rs739837 (pertaining to the vitamin D receptor) compared to the GG genotype. Similarly, the TT genotype of rs10190 was associated with significantly lower serum phosphate levels compared to CC and CT genotypes. Additionally, a lower serum PTH level was noted in individuals with the CT of rs1802757 (calcium-sensing receptor) compared to those with the CC genotype. Our machine learning analysis identified rs2221266 and rs1042636 as the most significant SNPs linked to vitamin D deficiency, demonstrating considerable predictive accuracy.</p><p><strong>Conclusions: </strong>Our findings indicate that specific single nucleotide polymorphisms in the vitamin D and calcium-sensing receptors significantly influence calcium metabolism biomarkers in ESRD patients. Assessing the clinical implications of these genetic variations is crucial for advancing personalized medicine in renal care.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 22","pages":"4634-4643"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.26355/eurrev_202411_36905
Y Yu, J-D Zhao, H Yang
The article "MiR-299-3p inhibits proliferation and invasion of cervical cancer cell via targeting TCF4" by Y. Yu, J.-D. Zhao, H. Yang published in Eur Rev Med Pharmacol Sci 2019; 23 (13): 5621-5627-DOI: 10.26355/eurrev_201907_18296-PMID: 31298314 has been retracted by the Editor in Chief. Following some concerns raised on PubPeer (link: https://pubpeer.com/publications/4275612B2FA-7C9A9CD7255B791D3A6), the Editor in Chief has started an investigation to assess the validity of the results as well as possible figure manipulation. The journal's investigation revealed data fabrication and several figure manipulations. Specifically, duplications were found within Figures 2C, 2F, 3C, 4A, and 4E. Moreover, Figure 2 (C, D, E), Figure 3C, and Figure 4 (C-D) contained duplications from previously published articles. The authors have been informed about the journal's investigation but remained unresponsive and have not provided the study's raw data. Consequently, the Editor in Chief decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18296.
Y. Yu, J.-D. Zhao, H. Yang的文章 "MiR-299-3p inhibits proliferation and invasion of cervical cancer cell via targeting TCF4 "发表在《Eur Rev Med Pharmacol Sci 2019; 23 (13): H. Yang》上。Zhao, H. Yang 发表在《Eur Rev Med Pharmacol Sci 2019; 23 (13):5621-5627-DOI: 10.26355/eurrev_201907_18296-PMID: 31298314 已被主编撤回。在PubPeer(链接:https://pubpeer.com/publications/4275612B2FA-7C9A9CD7255B791D3A6)上提出了一些疑虑之后,主编已开始调查,以评估结果的有效性以及可能存在的数据篡改。期刊的调查发现了数据捏造和一些图表篡改。具体来说,在图 2C、2F、3C、4A 和 4E 中发现了重复。此外,图 2(C、D、E)、图 3C 和图 4(C-D)与之前发表的文章重复。本刊已向作者通报了调查情况,但他们一直没有回应,也没有提供研究的原始数据。因此,主编决定撤回这篇文章。这篇文章已被撤回。出版商对此造成的不便深表歉意。https://www.europeanreview.org/article/18296。
{"title":"Retraction Note: MiR-299-3p inhibits proliferation and invasion of cervical cancer cell via targeting TCF4.","authors":"Y Yu, J-D Zhao, H Yang","doi":"10.26355/eurrev_202411_36905","DOIUrl":"10.26355/eurrev_202411_36905","url":null,"abstract":"<p><p>The article \"MiR-299-3p inhibits proliferation and invasion of cervical cancer cell via targeting TCF4\" by Y. Yu, J.-D. Zhao, H. Yang published in Eur Rev Med Pharmacol Sci 2019; 23 (13): 5621-5627-DOI: 10.26355/eurrev_201907_18296-PMID: 31298314 has been retracted by the Editor in Chief. Following some concerns raised on PubPeer (link: https://pubpeer.com/publications/4275612B2FA-7C9A9CD7255B791D3A6), the Editor in Chief has started an investigation to assess the validity of the results as well as possible figure manipulation. The journal's investigation revealed data fabrication and several figure manipulations. Specifically, duplications were found within Figures 2C, 2F, 3C, 4A, and 4E. Moreover, Figure 2 (C, D, E), Figure 3C, and Figure 4 (C-D) contained duplications from previously published articles. The authors have been informed about the journal's investigation but remained unresponsive and have not provided the study's raw data. Consequently, the Editor in Chief decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18296.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4490"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.26355/eurrev_202411_36953
V Issaris, G P Milas, C G Dragonas, G Poupouzas, N Anagnostopoulos, N Rovina
Objective: Acute respiratory distress syndrome (ARDS) is a systemic disease with high morbidity and mortality. Dead space fraction (Vd/Vt) represents the volume of air that does not participate in gas exchange and accurately depicts the pathophysiology of ARDS due to ventilation and perfusion mismatch. In this study, we aim to conduct a systematic review and meta-analysis regarding its usefulness for predicting mortality.
Materials and methods: We performed a systematic literature search identifying comparative studies meeting the above criteria from four databases: MEDLINE, clinicaltrials.gov, CENTRAL, and Google Scholar. A statistical meta-analysis was conducted utilizing the "meta" package in R software, with the included studies assessed based on the Newcastle-Ottawa scale.
Results: A total of twelve studies were included and data from over 1,700 patients was collected. Patients with higher levels of Vd/Vt were more likely to not survive with an OR=1.27 [95% CI (1.09, 1.48), I2=93%, p<0.01]. In addition, non-survivors of ARDS had higher mean value levels of Vd/Vt than survivors with an MD=0.07 [95% CI (0.02, 0.11), I2=82%, p<0.01]. Furthermore, a leave-one-out meta-analysis was performed in order to assess the effect of each individual study on the overall outcome, which led to the lowering of heterogeneity to 0.
Conclusions: The Vd/Vt ratio is an accurate index for determining the mortality of ARDS, reflecting the severity of the disease.
目的:急性呼吸窘迫综合征(Acute respiratory distress syndrome, ARDS)是一种高发病率、高死亡率的全身性疾病。死空分数(Vd/Vt)代表不参与气体交换的空气体积,准确描述了通气与灌注失配导致ARDS的病理生理。在这项研究中,我们的目标是对其预测死亡率的有效性进行系统回顾和荟萃分析。材料和方法:我们进行了系统的文献检索,从MEDLINE、clinicaltrials.gov、CENTRAL和谷歌Scholar四个数据库中确定符合上述标准的比较研究。利用R软件中的“meta”包进行统计荟萃分析,并根据纽卡斯尔-渥太华量表对纳入的研究进行评估。结果:共纳入12项研究,收集了1700多名患者的数据。较高Vd/Vt水平的患者更有可能无法生存,OR=1.27 [95% CI (1.09, 1.48), I2=93%],结论:Vd/Vt比值是判断ARDS死亡率的准确指标,反映了疾病的严重程度。
{"title":"The dead space fraction as a prognostic death indicator in patients with ARDS: a systematic review and meta-analysis.","authors":"V Issaris, G P Milas, C G Dragonas, G Poupouzas, N Anagnostopoulos, N Rovina","doi":"10.26355/eurrev_202411_36953","DOIUrl":"10.26355/eurrev_202411_36953","url":null,"abstract":"<p><strong>Objective: </strong> Acute respiratory distress syndrome (ARDS) is a systemic disease with high morbidity and mortality. Dead space fraction (Vd/Vt) represents the volume of air that does not participate in gas exchange and accurately depicts the pathophysiology of ARDS due to ventilation and perfusion mismatch. In this study, we aim to conduct a systematic review and meta-analysis regarding its usefulness for predicting mortality.</p><p><strong>Materials and methods: </strong>We performed a systematic literature search identifying comparative studies meeting the above criteria from four databases: MEDLINE, clinicaltrials.gov, CENTRAL, and Google Scholar. A statistical meta-analysis was conducted utilizing the \"meta\" package in R software, with the included studies assessed based on the Newcastle-Ottawa scale.</p><p><strong>Results: </strong>A total of twelve studies were included and data from over 1,700 patients was collected. Patients with higher levels of Vd/Vt were more likely to not survive with an OR=1.27 [95% CI (1.09, 1.48), I2=93%, p<0.01]. In addition, non-survivors of ARDS had higher mean value levels of Vd/Vt than survivors with an MD=0.07 [95% CI (0.02, 0.11), I2=82%, p<0.01]. Furthermore, a leave-one-out meta-analysis was performed in order to assess the effect of each individual study on the overall outcome, which led to the lowering of heterogeneity to 0.</p><p><strong>Conclusions: </strong>The Vd/Vt ratio is an accurate index for determining the mortality of ARDS, reflecting the severity of the disease.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 22","pages":"4561-4575"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.26355/eurrev_202411_36909
F Alzoughool, R Abdelqader, S Abumweis, A Al-Bashaireh, Y Aljawarneh, M Alzghool, L Alanagreh
Objective: The recently discovered protein adropin is a highly conserved polypeptide that plays critical functions in energy homeostasis, metabolic processes, fat metabolism, and insulin resistance. On the other hand, non-alcoholic fatty liver disease (NAFLD) is a medical condition that causes the buildup of fat in the liver cells in individuals who consume little or no alcohol. The frequency of NAFLD is rising globally, and it is frequently linked to obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Therefore, this study evaluates the association between adropin levels and insulin resistance in individuals with and without NAFLD.
Materials and methods: Data from Scopus, Science Direct, and PubMed were searched between January 1, 2012, and February 18, 2024, using precise terms and stated criteria. Comprehensive Meta-Analysis V. 2 (Biostat, Englewood, NJ, USA) was used for data analysis, and Random-effect models were used to estimate the pooled mean differences with 95% CIs of adropin level, insulin level, and homeostatic model assessment for insulin resistance (HOMA-IR) associated with the exposures of interest.
Results: Our results revealed that adropin blood levels are significantly reduced in NAFLD patients compared to control individuals. The mean difference in adropin blood levels was 2.391 ng/ml with a 95% CI of 1.127 to 3.656 with I2 99.6. on the other hand, insulin resistance was significantly higher in NAFLD compared to controls (MD: -1.668, 95% CI: -2.333 to -1.002, I2=86%).
Conclusions: Our findings reveal that adropin levels are significantly greater in healthy controls than in NAFLD patients, suggesting that adropin may have a preventative effect on NAFLD. This meta-analysis highlights how closely adropin and insulin resistance interact in non-alcoholic fatty liver disease. Also, it may open the door to new diagnostic tools and therapeutic modalities.
{"title":"Evaluation of adropin level and insulin resistance in non-alcoholic fatty liver patients: a meta-analysis of studies.","authors":"F Alzoughool, R Abdelqader, S Abumweis, A Al-Bashaireh, Y Aljawarneh, M Alzghool, L Alanagreh","doi":"10.26355/eurrev_202411_36909","DOIUrl":"10.26355/eurrev_202411_36909","url":null,"abstract":"<p><strong>Objective: </strong>The recently discovered protein adropin is a highly conserved polypeptide that plays critical functions in energy homeostasis, metabolic processes, fat metabolism, and insulin resistance. On the other hand, non-alcoholic fatty liver disease (NAFLD) is a medical condition that causes the buildup of fat in the liver cells in individuals who consume little or no alcohol. The frequency of NAFLD is rising globally, and it is frequently linked to obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Therefore, this study evaluates the association between adropin levels and insulin resistance in individuals with and without NAFLD.</p><p><strong>Materials and methods: </strong>Data from Scopus, Science Direct, and PubMed were searched between January 1, 2012, and February 18, 2024, using precise terms and stated criteria. Comprehensive Meta-Analysis V. 2 (Biostat, Englewood, NJ, USA) was used for data analysis, and Random-effect models were used to estimate the pooled mean differences with 95% CIs of adropin level, insulin level, and homeostatic model assessment for insulin resistance (HOMA-IR) associated with the exposures of interest.</p><p><strong>Results: </strong>Our results revealed that adropin blood levels are significantly reduced in NAFLD patients compared to control individuals. The mean difference in adropin blood levels was 2.391 ng/ml with a 95% CI of 1.127 to 3.656 with I2 99.6. on the other hand, insulin resistance was significantly higher in NAFLD compared to controls (MD: -1.668, 95% CI: -2.333 to -1.002, I2=86%).</p><p><strong>Conclusions: </strong>Our findings reveal that adropin levels are significantly greater in healthy controls than in NAFLD patients, suggesting that adropin may have a preventative effect on NAFLD. This meta-analysis highlights how closely adropin and insulin resistance interact in non-alcoholic fatty liver disease. Also, it may open the door to new diagnostic tools and therapeutic modalities.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4507-4514"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}